Cure My Disease

Don't miss your cure!

 Log in / Sign up

New patch aims to fix knee cartilage – but study halted early

NCT ID NCT05785949

Disease control Sponsor: Geistlich Pharma AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a special collagen membrane (Chondro-Gide®) to help repair damaged knee cartilage in 75 people aged 18-55. The goal was to see if the membrane safely improves cartilage healing, measured by MRI scans and knee function scores. The trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

75 people

The number who actually took part.

Started

Mar 2023

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female patients aged 18-55 years (including 18 years and 55 years); 2. Localized cartilage defects on knee joint, the size of the defect after debridement is 2.0 squared cm - 8.0 squared cm (including 2.0 squared cm and 8.0 squared cm), which was classified by the International Cartilage Repair Society (ICRS) as grade Ⅲ or grade IV; 3. The subjects voluntarily consent to participate in this trial and sign the informed consent form (ICF). Exclusion Criteria: 1. Body mass index (BMI) ≥ 30 kg/meter squared (BMI = weight divided by height squared); 2. Unilateral knee cartilage defect with the ICRS classification of grade III or grade IV, and with three or more defects; 3. Patients with abnormal lower limb mechanical axis requiring correction, except those that could be corrected during the treatment of cartilage injury; 4. Varus or valgus of lower limb axis \> 5°, requiring osteotomy for correction; 5. Patients with multiple ligament injury or total meniscectomy; 6. Those who are known to be allergic to porcine-derived materials or collagen, or refuse to use porcine-derived medical products; 7. Those with severe arthroclisis or arthrofibrosis; 8. Those who have received open knee surgery in the past 6 months; 9. Those who have received microfracture, mosaicplasty or autologous cartilage implantation in the past 3 months; 10. Those who have serious primary cardiovascular diseases, lung diseases, endocrine and metabolic diseases (severe diabetes, severe osteoporosis) or serious diseases affecting their survival, and are considered unsuitable for inclusion by the investigators; 11. Pregnant and lactating women, or those who plan to conceive during the trial, and those who have positive blood/urine pregnancy test results before the trial; 12. Patients with knee infection； 13. Those with connective tissue diseases; 14. Those with nervous system diseases or muscle degeneration; 15. Patients who participated in drug clinical trials within 3 months prior to the enrollment or patients who participated in any other device clinical trials within 1 months prior to the enrollment; 16. Other circumstances which are considered by the investigator not suitable for enrollment in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cartilage defects are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

articular cartilage disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cartilage defects

Contacts and locations

Locations

  • Inner Mongolia People's Hospital

    Hohhot, 010011, China

  • Nan Chang First Hospital

    Nanchang, Jiangxi, 330000, China

  • Peking University Shen Zhen hospital

    Shenzhen, Guangdong, 518036, China

  • Peking University Third Hospital

    Beijing, 100191, China

  • QiLu Hospital of Shan Dong University

    Jinan, Shandong, 250002, China

  • Shen Zhen Secondary People hospital

    Shenzhen, Guangdong, 518035, China

  • Sino-Japanese Friendship Hospital

    Beijing, 100013, China

  • Tai Zhou Hospital of Zhe Jiang Province

    Taizhou, Zhejiang, 318013, China

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    Nanjing, 210008, China

  • The First Affiliated Hospital Of Nanchang University

    Nanchang, 330209, China

  • The First Affiliated Hospital of Jinan University

    Guangzhou, 510632, China

  • The First Affiliated Hospital of Kunming Medical University

    Kunming, 650051, China

  • The First People Hospital of Ka Shi

    Kashgar, Xinjiang, 844000, China

  • The Second Hospital of Jilin University

    Changchun, 130041, China

  • The Second Hospital of Tang Shan

    Tangshan, Hebei, 063016, China

  • The Second People Hospital of Yi Bin

    Yibin, Guangdong, 644000, China

  • The Third Affiliated Hospital of Southern Medical University

    Guangzhou, 510640, China

  • The second affiliated hospital of Zhejiang University School of Medicine

    Hanzhou, 310009, China